Merck & Co., Inc. (NYSE:MRK) Shares Bought by Marietta Wealth Management LLC

Marietta Wealth Management LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 10.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,378 shares of the company’s stock after purchasing an additional 4,085 shares during the period. Marietta Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $3,641,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in MRK. Norges Bank acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $1,823,028,000. BlackRock Inc. raised its stake in shares of Merck & Co., Inc. by 5.5% in the fourth quarter. BlackRock Inc. now owns 198,224,263 shares of the company’s stock valued at $15,191,909,000 after acquiring an additional 10,326,974 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Merck & Co., Inc. by 12.7% in the fourth quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company’s stock valued at $3,682,009,000 after acquiring an additional 5,409,154 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Merck & Co., Inc. by 13.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 28,981,674 shares of the company’s stock valued at $2,221,156,000 after acquiring an additional 3,484,786 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Merck & Co., Inc. by 2.7% in the fourth quarter. State Street Corp now owns 118,668,673 shares of the company’s stock valued at $9,174,491,000 after acquiring an additional 3,132,078 shares in the last quarter. Institutional investors own 72.88% of the company’s stock.

Shares of MRK stock opened at $89.16 on Thursday. The stock’s 50-day moving average is $88.75 and its two-hundred day moving average is $82.17. The firm has a market cap of $225.47 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 1.19 and a beta of 0.36. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $94.92. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.14 and a current ratio of 1.40.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.81 by $0.33. The company had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The business’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.40 earnings per share. As a group, research analysts predict that Merck & Co., Inc. will post 7.32 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 8th. Investors of record on Wednesday, June 15th will be issued a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date is Tuesday, June 14th. Merck & Co., Inc.’s dividend payout ratio is currently 49.37%.

Several analysts have recently issued reports on MRK shares. Morgan Stanley reduced their price objective on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Barclays increased their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, April 12th. SVB Leerink restated an “outperform” rating and issued a $102.00 price target on shares of Merck & Co., Inc. in a research note on Monday, June 6th. StockNews.com assumed coverage on Merck & Co., Inc. in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Finally, Mizuho assumed coverage on Merck & Co., Inc. in a research note on Friday, April 1st. They issued a “buy” rating and a $100.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.60.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.